Viewing Study NCT02296918

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 5:03 AM
Ignite Modification Date: 2026-02-21 @ 10:34 AM
Study NCT ID: NCT02296918
Status: COMPLETED
Last Update Posted: 2025-12-19
First Post: 2014-11-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Sponsor: Acerta Pharma BV
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Lymphocytic Leukemia View
None Small Lymphocytic Lymphoma View
None Prolymphocytic Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CLL View
None SLL View
None PLL View
None Chronic Lymphocytic Leukemia View
None Small Lymphocytic Lymphoma View
None Prolymphocytic Leukemia View
None ACP-196 View
None acalabrutinib View
None obinutuzumab View
None rituximab View
None venetoclax View